Cargando…
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Combination therapies are superior to monotherapy for many cancers. This advantage was historically ascribed to the ability of combinations to address tumor heterogeneity, but synergistic interaction is now a common explanation as well as a design criterion for new combinations. We review evidence t...
Autores principales: | Plana, Deborah, Palmer, Adam C., Sorger, Peter K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904281/ https://www.ncbi.nlm.nih.gov/pubmed/34983746 http://dx.doi.org/10.1158/2159-8290.CD-21-0212 |
Ejemplares similares
-
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials
por: Palmer, Adam C., et al.
Publicado: (2020) -
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects
por: Plana, Deborah, et al.
Publicado: (2022) -
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
por: Palmer, Adam C, et al.
Publicado: (2019) -
Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015) -
Tumor-specific activity of precision medicines in the NCI-MATCH trial
por: Zhou, Ivvone, et al.
Publicado: (2023)